Globalink Investment is a SPAC — a blank check company with no operations of its own. Globalink raised approximately $116.7M in its December 2021 IPO, with proceeds held in a trust account invested in U.S. government securities pending a merger. The SPAC's sole purpose is to identify a private company, merge with it, and take it public, bypassing the traditional IPO process. Globalink has focused its search on medical technology and green energy companies with enterprise values between $80M and $2B, primarily in North America, Europe, and Southeast Asia. In January 2024, Globalink signed a merger agreement with Alps Life Sciences at an implied enterprise value of $1.6B, structured as an all-equity transaction. The deal has been amended multiple times and remains open. Globalink faces a hard deadline of June 9, 2025 to close the merger or liquidate and return remaining trust funds to shareholders. The SPAC's situation is challenged: the vast majority of public shares have been redeemed across three extension votes, leaving very few public shares outstanding and a depleted trust, and Globalink was delisted from Nasdaq in December 2024 after exceeding the 36-month listing limit, with its securities now trading on OTC Pink. The Alps Life Sciences Form F-4 registration statement was filed with the SEC in December 2024 but had not yet been declared effective as of the filing date.